<DOC>
	<DOCNO>NCT00361231</DOCNO>
	<brief_summary>The purpose study test safety bevacizumab give combination gemcitabine oxaliplatin see effect ( good bad ) combination patient cancer bile duct gallbladder . Bevacizumab show slow stop cell growth tumor decrease blood supply tumor .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin Combination With Bevacizumab Biliary Tract Gallbladder Cancer</brief_title>
	<detailed_description>- The chemotherapy drug give twice every 28 day . This 28 day period call cycle study treatment . - Bevacizumab administer IV 90 minute day 1 day 15 . Gemcitabine administer IV 1 hour 40 minute day 1 15 cycle . Oxaliplatin administer IV 2 hour day 1 15 cycle . - The following test procedure perform day 1 day 15 cycle : physical examination ; medical history ; blood work ; urine test . A PET scan repeat end cycle 2 CT scan repeat every 8 week . - Participants continue receive cycle study treatment long disease progress experience serious side effect .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm , locally unresectable metastatic biliary tract gallbladder adenocarcinoma . Patients must least one measurable lesion outside prior radiation field . Zero one prior chemotherapy biliary tract gallbladder cancer Age &gt; 18 year ECOG performance status 02 Life expectancy &gt; 12 week Adequate organ bone marrow function Chemotherapy within past 3 week initiation therapy Pregnant lactate woman Clinically apparent central nervous system metastases carcinomatous meningitis Biliary obstruction inadequate drainage total bilirubin &gt; 2.5 mg/dL Concurrent malignancy site , except limited basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix Uncontrolled serious medical psychiatric illness Preexisting peripheral neuropathy grade 2 great severity accord Common Terminology Criteria NCI ( version 3.0 ) Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Blood pressure &gt; 150/100 mmHg Unstable angina NYHA Grade II great congestive heart failure History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury 28 day prior Day 1 , anticipation need major surgical procedure course study History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior day 1 Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Avastin</keyword>
	<keyword>GEMOX</keyword>
</DOC>